Cingulate Inc. Postpones Special Meeting of Stockholders
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical firm known for its innovative Precision Timed Release™ (PTR™) drug delivery platform, has decided to postpone its Special Meeting of Stockholders. This extension allows more stockholders to participate in voting on important proposals. The adjournment was necessary because there were not enough shares present, either through remote communication or by proxy, to meet the quorum requirements.
Why the Meeting Was Postponed
The Board of Directors at Cingulate is dedicated to giving stockholders the chance to express their views on all proposals outlined in the proxy statement. By postponing the meeting, the Company hopes to gather enough votes to accurately represent the interests of its stakeholders. The proposals being considered are seen as beneficial and strategic for advancing the Company's long-term goals and operational efficiency.
New Meeting Schedule
The rescheduled Special Meeting of Stockholders will now occur at 11:00 a.m. Central Time on August 28, 2024. Stockholders will meet virtually at a specified web address to cast their votes. The Company is committed to making sure every voice is heard and is encouraging participation through various voting platforms.
Voting Instructions for Stockholders
Stockholders are invited to participate by casting their votes live, either by calling a dedicated toll-free number or by using the online voting portal set up for this purpose. This approach is designed to make participation easier for all stockholders, reflecting Cingulate’s commitment to transparency and engagement.
Significance of Stockholder Engagement
Active participation from stockholders is vital for making informed decisions about the Company's future. The involvement of stakeholders during this meeting will help shape the direction of Cingulate’s strategic initiatives, including ongoing work on its extensive pipeline of pharmaceutical products aimed at treating conditions like attention deficit/hyperactivity disorder (ADHD).
About Cingulate Inc.
Cingulate Inc. is dedicated to advancing healthcare solutions through its unique PTR™ drug delivery system, which is designed to enhance therapeutic effectiveness and simplify medication regimens for patients. While its initial focus is on ADHD, Cingulate is also exploring additional therapeutic areas, such as anxiety disorders, where their platform can offer significant advantages. This ongoing innovation positions Cingulate as a forward-thinking entity in the biopharmaceutical sector.
Contacting Investor Relations
For any inquiries related to investor relations, stockholders and interested parties can reach out to:
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
Email: TDalton@cingulate.com
Phone: 913-942-2301
Matt Kreps
Darrow Associates
Email: mkreps@darrowir.com
Phone: 214-597-8200
Frequently Asked Questions
What led to the postponement of the Special Meeting?
The meeting was postponed because there were not enough shares present to meet the quorum, ensuring that all stockholders have the chance to vote on key proposals.
When is the new date for the Special Meeting?
The Special Meeting has been rescheduled for August 28, 2024, at 11:00 a.m. Central Time.
How can stockholders participate in voting?
Stockholders can cast their votes live by calling a toll-free number or through the designated online voting portal during the meeting.
What key proposals will be discussed at the meeting?
The main proposals include various strategic initiatives put forth by the Board of Directors, which are believed to be in the best interests of Cingulate's stockholders.
Who can stockholders contact for more information?
Stockholders can reach out to Thomas Dalton or Matt Kreps for inquiries related to investor relations and additional information about the Company.
